Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Cleveland, Ohio.
Southeast Radiation Oncology Group, Charlotte, North Carolina.
Cancer. 2018 Apr 1;124(7):1400-1414. doi: 10.1002/cncr.31213. Epub 2018 Jan 9.
Time to treatment initiation (TTI) is increasing and is associated with worsening survival. In the current study, the authors sought to identify a mechanism for this relationship by assessing the effect of TTI on clinical-to-pathologic upstaging in patients with head and neck squamous cell carcinoma (HNSCC).
Using the National Cancer Data Base, the authors analyzed patients receiving definitive surgery for SCC of the oral cavity, oropharynx, larynx, and hypopharynx from 2005 through 2014. The primary outcome was T, N, or stage group upstaging, defined as higher pathologic stage than clinical stage. TTI was defined as the time between diagnosis and surgery. Multivariable logistic and Cox proportional hazards regression modeled upstaging and survival, respectively.
Cohorts of 60,194 patients, 51,380 patients, and 52,980 patients, respectively, with complete T, N, and stage group data were included. N upstaging was most common (18.6%), followed by stage group (17.4%) and T (12.1%) upstaging; all types were predicted by TTI. Compared with a TTI of 1 to 6 days, TTIs as short as 7 to 13 days (odds ratio, 1.20; P = .038) or ≥ 70 days (odds ratio, 2.04; P < .001) were found to predict T upstaging, a finding that is consistent for N and stage group upstaging. Using restricted cubic splines, relative odds of T and stage group upstaging escalated to 2.25 and 1.93, respectively, at a TTI of 365 days. In survival analyses, T (hazard ratio [HR], 1.53), N (HR, 1.88), and stage group (HR, 1.69) upstaging all predicted mortality (P < .001), whereas TTI only predicted mortality after 70 days (HR, 1.11; P = .023).
Tumor progression, measured by clinical-to-pathologic upstaging, increases mortality for patients with HNSCC experiencing treatment delays. Cancer 2018;124:1400-14. © 2018 American Cancer Society.
治疗起始时间(TTI)不断延长,与生存预后恶化相关。在本研究中,作者试图通过评估 TTI 对头颈部鳞状细胞癌(HNSCC)患者临床-病理分期升级的影响来确定这种关系的机制。
作者利用国家癌症数据库,分析了 2005 年至 2014 年间接受口腔、口咽、下咽和喉 SCC 根治性手术的患者。主要结局是 T、N 或分期组升级,定义为高于临床分期的病理分期。TTI 定义为从诊断到手术的时间。多变量逻辑和 Cox 比例风险回归分别对升级和生存进行建模。
分别纳入了 60194 例、51380 例和 52980 例具有完整 T、N 和分期组数据的患者队列。N 升级最为常见(18.6%),其次是分期组(17.4%)和 T(12.1%)升级;所有类型均与 TTI 相关。与 TTI 为 1 至 6 天相比,TTI 短至 7 至 13 天(优势比,1.20;P=0.038)或≥70 天(优势比,2.04;P<0.001)被发现可预测 T 升级,这一发现与 N 和分期组升级一致。使用限制性立方样条,TTI 为 365 天时,T 和分期组升级的相对优势分别上升至 2.25 和 1.93。在生存分析中,T(危险比[HR],1.53)、N(HR,1.88)和分期组(HR,1.69)升级均预测死亡(P<0.001),而 TTI 仅在 TTI 超过 70 天后预测死亡(HR,1.11;P=0.023)。
肿瘤进展,通过临床-病理分期升级来衡量,会增加 HNSCC 患者因治疗延迟而死亡的风险。癌症 2018;124:1400-14。©2018 美国癌症协会。